Current Report Filing (8-k)
May 31 2017 - 4:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
May 24, 2017
Repros Therapeutics Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other
Jurisdiction of
Incorporation)
|
001-15281
(Commission File
Number)
|
76-0233274
(I.R.S. Employer
Identification No.)
|
2408 Timberloch Place, Suite B-7
|
|
|
The Woodlands, TX
|
|
77380
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(281) 719-3400
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in
Rule 405
of
the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter)
.
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On May 24, 2017, Jaye Thompson, Ph.D., Senior Vice President
of Clinical and Regulatory of Repros Therapeutics Inc. (the “Company”), separated from the Company, effective May 24,
2017. Dr. Thompson is expected to enter into a separation agreement with the Company in the near future that will provide for a
severance payment consisting of six and one-half months of salary and the continuation of Company-paid benefits for a six month
period, as well as providing for Dr. Thompson to have two years to exercise her vested stock options outstanding as of her retirement.
The separation agreement is also expected to provide that Dr. Thompson is bound by certain restrictive covenants, including non-compete
and non-solicitation provisions, and to contain a release by Dr. Thompson of all claims against the Company, subject to certain
enumerated exceptions.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
REPROS THERAPEUTICS INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Kathi Anderson
|
|
|
|
Kathi Anderson
|
|
|
|
CFO
|
|
Dated: May 31, 2017
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024